Table 2 Summary of the clinical features of primary mammary diffuse large B-cell lymphoma

No.	Age	Size (cm) ^a	Side	LDH ratio	IPI ^b	Stage	Operation	Chemotherapy	Relapse	Outcome	Follow-up (month)
1	77	7.0 × 6.0	Rt.	1.92	2	IIE	MRM	CHOP		Alive	7
2	63	5.6 × 4.8	Lt.		1/2	IE	Excision	MACOP-B	Bladder, abdominal tumor^c; 43 mo	AWD	46
3	60	2.1 × 1.8	Lt.		1/2	IE	MRM	THP-COP		Alive	35
4	45	4.0 × 3.0	Rt.	1.10	1	IE	Excision	CHOP		Alive	5
5	68	6.5 × 3.5	Rt.	1.89	2	IE	RM	VEPA		Alive	171
6	63	9.8 × 8.5	Lt.	0.94	1	IE	MRM	None	Subcutaneous tumor (left chest wall); 1 mo	DOD	5
7	71	2.6 × 2.4	Lt.		1/2	IE	MRM	THP-COP		Alive	63
8	73	5.0 × 4.0	Lt.	1.21	2	IE	RM	CHOP, CPA+VC+VDS	Local, bone marrow, spleen; 10 mo	DOD	17
9	77	2.8 × 2.8	Lt.	1.92	2	IE	Excision	THP-COP+RT		Alive	8
10	69	5.2 × 5.1	Lt.	1.16	2	IE	MRM	None		Alive	3
11	81	6.8 × 4.9	Lt.	1.03	2	IE	MRM	Half-CHOP without ADM	Mandible lymph node; 13 mo	DOD	16
12	66	6.5 × 5.8	Rt.	0.80	1	IE	MRM	CHOP	Opposite breast; 81 mo	AWD	81
13	76	7.0 × 6.0	Lt.	0.75	1	IIE	MRM	low-dose CHOP		Alive	12
14	60	9.5 × 6.5	Lt.	1.02	1	IE	MRM	CHOP		Alive	4
15	53	5.5 × 5.5	Lt.		0/1	IE	Excision	VEPA	Opposite breast; 38 mo	DOD	94

Alive: alive without disease; AWD: alive with disease; CHOP: cyclophosphamide, adriamycin, vincristine, prednisolone; DOD: dead on disease; IPI: International Prognostic Index; LDH ratio: measured value/normal value; MRM: modified radical mastectomy; MACOP-B: methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisolone, bleomycin; RT: radiation therapy; RM: radical mastectomy; THP-COP: cyclophosphamide, THP-doxorubicin (pirarubicin), vincristine, prednisolone; VC: vincristine; VDS: vindesine; VEPA: vinblastine, etoposide, prednisone, doxorubicin; mo: months.
^aTumor size was decided by palpation.
^ba/b means that IPI was a or b because the LDH ratio of the patient was unknown.
^crelapse lesions in bladder and abdomen were DLBCL.

Search